参考文献(References)：
[1] PRINGSHEIM T,JETTE N,FROLKIS A,et al.The prevalence of Parkinson’s disease:a systematic review and meta-analysis[J].Movement Disorders,2014,29(13):1583.
[2] XU T L,DONG W L,LIU J L,et al.Disease burden of Parkinson’s disease in China and its provinces from 1990 to 2021:findings from the global burden of disease study 2021[J].The Lancet Regional Health Western Pacific,2024,46:101078.
[3] 张倩茹，朱冬雨，陆征宇，等.α-突触核蛋白在帕金森病发病机制和治疗中的研究进展[J].神经损伤与功能重建，2018,13(2):86.
[4] GUERRERO-MU??OZ J M,CASTILLO-CARRANZA L D,KAYED R.Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins[J].Biochemical Pharmacology,2014,88(4):468.
[5] CHEN L,HUANG G L,LYU M H,et al.Amide derivatives of gallic acid:design,synthesis and evaluation of inhibitory activities against in vitro α-synuclein aggregation[J].Bioorganic & Medicinal Chemistry,2020,28(15):115596.
[6] LI X L,ZHANG Y N,WANG Y,et al.The mechanisms of trad-itional Chinese medicine underlying the prevention and treatment of Parkinson’s disease[J].Frontiers in Pharmacology,2017,8:634.
[7] XU Y,ZHANG Y Y,QUAN Z Z,et al.Epigallocatechin gallate (EGCG) inhibits alpha-synuclein aggregation:a potential agent for Parkinson’s disease[J].Neurochemical Research,2016,41(10):2788.
[8] HIDESHIMA M,KIMURA Y,AGUIRRE C,et al.Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease[J].Scientific Reports,2022,12:351.
[9] ONO K,YAMADA M.Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro[J].Journal of Neurochemistry,2006,97(1):105.
[10] FAN Q,LIU Y L,WANG X Y,et al.Ginnalin a inhibits aggregation,reverses fibrillogenesis,and alleviates cytotoxicity of amyloid β(1-42)[J].ACS Chemical Neuroscience,2020,11(4):638.
[11] LIU Y Q,CARVER J A,CALABRESE A N,et al.Gallic acid interacts with α-synuclein to prevent the structural collapse necessary for its aggregation[J].BBA:Proteins and Proteomics,2014,1844(9):1481.
[12] ROGERS K J,ANGEL A,BUTTERFIELD L.The penetration of catechol and pyrogallol into mouse brain and the effect on cerebral monoamine levels[J].Journal of Pharmacy and Pharmacology,2011,20(9):727.
[13] BOPARDIKAR M,KOTI AINAVARAPU S R,HOSUR R V.Pyrogallol,Corilagin and Chebulagic acid target the “fuzzy coat” of alpha-synuclein to inhibit the fibrillization of the protein[J].RSC Advances,2022,12(55):35770.
[14] SURMEIER D J,OBESO J A,HALLIDAY G M.Parkinson’s disease is not simply a prion disorder[J].The Journal of Neuroscience,2017,37(41):9799.
[15] LI B S,GE P,MURRAY K A,et al.Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel[J].Nature Communications,2018,9:3609.
[16] VOLPICELLI-DALEY L A,LUK K C,PATEL T P,et al.Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death[J].Neuron,2011,72(1):57.
[17] WINNER B,JAPPELLI R,MAJI S K,et al.In vivo demonstration that alpha-synuclein oligomers are toxic[J].Proceedings of the National Academy of Sciences of the United States of America,2011,108(10):4194.
[18] LASHUEL H A,OVERK C R,OUESLATI A,et al.The many faces of α-synuclein:from structure and toxicity to therapeutic target[J].Nature reviews.Neuroscience,2013,14(1):38.
[19] UEHARA T,CHOONG C J,NAKAMORI M,et al.Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease[J].Scientific Reports,2019,9(1):1.
